GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InVivo Therapeutics Holdings Corp (OTCPK:NVIVQ) » Definitions » 5-Year RORE %

InVivo Therapeutics Holdings (InVivo Therapeutics Holdings) 5-Year RORE % : -74.06% (As of Sep. 2023)


View and export this data going back to 2010. Start your Free Trial

What is InVivo Therapeutics Holdings 5-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. InVivo Therapeutics Holdings's 5-Year RORE % for the quarter that ended in Sep. 2023 was -74.06%.

The industry rank for InVivo Therapeutics Holdings's 5-Year RORE % or its related term are showing as below:

NVIVQ's 5-Year RORE % is ranked worse than
94.56% of 1067 companies
in the Biotechnology industry
Industry Median: -7.34 vs NVIVQ: -74.06

InVivo Therapeutics Holdings 5-Year RORE % Historical Data

The historical data trend for InVivo Therapeutics Holdings's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InVivo Therapeutics Holdings 5-Year RORE % Chart

InVivo Therapeutics Holdings Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
5-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.31 -36.93 -36.31 -61.16 -89.69

InVivo Therapeutics Holdings Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -90.13 -89.69 -89.05 -65.12 -74.06

Competitive Comparison of InVivo Therapeutics Holdings's 5-Year RORE %

For the Biotechnology subindustry, InVivo Therapeutics Holdings's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InVivo Therapeutics Holdings's 5-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InVivo Therapeutics Holdings's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where InVivo Therapeutics Holdings's 5-Year RORE % falls into.



InVivo Therapeutics Holdings 5-Year RORE % Calculation

InVivo Therapeutics Holdings's 5-Year RORE % for the quarter that ended in Sep. 2023 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( -3.29--884.682 )/( -1190.051-0 )
=881.392/-1190.051
=-74.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2023 and 5-year before.


InVivo Therapeutics Holdings  (OTCPK:NVIVQ) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


InVivo Therapeutics Holdings 5-Year RORE % Related Terms

Thank you for viewing the detailed overview of InVivo Therapeutics Holdings's 5-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


InVivo Therapeutics Holdings (InVivo Therapeutics Holdings) Business Description

Traded in Other Exchanges
Address
One Kendall Square, Suite B14402, Building 1400 West, 4th Floor, Cambridge, MA, USA, 02139
InVivo Therapeutics Holdings Corp is a research and clinical stage biomaterials and biotechnology company. It focuses on the treatment of spinal cord injury. The company's product pipeline consists of Neuro spinal scaffold and Bioengineered neural trails. The firm has a clinical development program for acute spinal cord injury and a preclinical development program for chronic spinal cord injury.
Executives
Brice Foose 10 percent owner 236 SILENT MEADOW DRIVE, LAKE ST. LOUIS MO 63367
Daniel R Marshak director C/O CAMBREX CORP, ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ 07073
Christina Morrison director ARAMARK, 1101 MARKET STREET, PHILADELPHIA PA 19107
Richard M. Toselli director, officer: CEO and CMO C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Richard Christopher officer: Chief Financial Officer C/O LUCID, INC., 50 METHODIST HILL DR, SUITE 1000, ROCHESTER NY 14623
C Ann Merrifield director
Bob Rosenthal director 20 NEWBURY ST, BOSTON MA 02116
Heather Hamel officer: Chief Legal Officer and GC ONE KENDALL SQUARE, BUILDING 1400 WEST, FLOOR 4, CAMBRIDGE MA 02139
Jeffrey Modestino officer: See Remarks C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14403, CAMBRIDGE MA 02139
Christopher Mcnulty officer: Chief Financial Officer C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Melanie Golarz officer: Interim CFO C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Jeffrey S. Hatfield director 11080 ROSELLE STREET, SAN DIEGO CA 92121
Pamela J Stahl officer: Chief Commercial Officer ONE KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Richard John Roberts director ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Masuoka K. Lorianne officer: Chief Medical Officer C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070